Brokerages Set OrthoPediatrics Corp. (NASDAQ:KIDS) Price Target at $24.00

OrthoPediatrics Corp. (NASDAQ:KIDS) has been given an average rating of “Moderate Buy” by the ten analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $24.00.

A number of research firms have issued reports on KIDS. JMP Securities lowered their target price on OrthoPediatrics from $35.00 to $25.00 and set a “market outperform” rating for the company in a report on Friday, October 10th. Needham & Company LLC decreased their price objective on OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. Lake Street Capital dropped their target price on OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, October 10th. Piper Sandler reduced their price target on OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Finally, Citigroup reaffirmed an “outperform” rating on shares of OrthoPediatrics in a research note on Friday, October 10th.

OrthoPediatrics Stock Performance

Shares of KIDS opened at $18.35 on Tuesday. The firm has a market cap of $460.22 million, a P/E ratio of -9.41 and a beta of 1.09. OrthoPediatrics has a twelve month low of $15.28 and a twelve month high of $27.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.52 and a current ratio of 7.40. The firm’s 50 day moving average price is $17.89 and its two-hundred day moving average price is $18.96.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.02. The company had revenue of $61.25 million during the quarter, compared to the consensus estimate of $63.63 million. OrthoPediatrics had a negative net margin of 20.06% and a negative return on equity of 6.86%. On average, analysts forecast that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Institutional Investors Weigh In On OrthoPediatrics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. lifted its position in OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after buying an additional 1,139 shares in the last quarter. Caption Management LLC acquired a new stake in shares of OrthoPediatrics in the third quarter valued at about $54,000. BNP Paribas Financial Markets increased its position in shares of OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,235 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in OrthoPediatrics during the second quarter worth about $220,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after purchasing an additional 645 shares during the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.